Clene Inc. plans to update its CNM-Au8 program for ALS during an investor call on December 3, 2025.
Quiver AI Summary
Clene Inc. and its subsidiary, Clene Nanomedicine Inc., announced plans to update investors on their CNM-Au8 program for amyotrophic lateral sclerosis (ALS) in a call and webcast scheduled for December 3, 2025, at 8:30 am ET. The event will feature presentations from key executives, including CEO Rob Etherington and Dr. Ben Greenberg, and will be accessible through a webcast link provided in the release. Clene focuses on treating neurodegenerative diseases like ALS and multiple sclerosis through its investigational therapy CNM-Au8, which utilizes gold nanocrystals to improve mitochondrial function, reduce oxidative stress, and support neuronal health. The company, based in Salt Lake City, also has R&D operations in Maryland. For further updates, interested parties can visit their website or follow them on social media.
Potential Positives
- Clene Inc. is poised to provide significant updates on its CNM-Au8 program in ALS, indicating progress in its drug development pipeline.
- The scheduled investor call and webcast demonstrate Clene's commitment to transparency and engagement with investors and stakeholders.
- CNM-Au8 is described as a first-in-class therapy, highlighting its novel approach and potential competitive advantage in treating neurodegenerative diseases.
Potential Negatives
- The press release does not provide any specific data or results regarding the CNM-Au8 program, which may lead to investor skepticism about the program's progress and effectiveness.
- There is a lack of information about potential regulatory hurdles or challenges faced in the development of CNM-Au8, which could impact investor confidence.
- Being a late clinical-stage company implies that Clene is under pressure to deliver results; any delays or negative outcomes could have significant negative implications for the company moving forward.
FAQ
What is the CNM-Au8 program in ALS?
CNM-Au8 is an investigational therapy aimed at improving neuronal health in ALS patients by enhancing mitochondrial function.
When is the Clene investor call and webcast?
The investor call and webcast will take place on December 3, 2025, at 8:30 a.m. ET.
How can I access the investor webcast?
The webcast can be accessed through the provided link or the Investors section of Clene's website.
Who are the presenters of the CNM-Au8 update?
The update will be presented by Rob Etherington, Dr. Ben Greenberg, and Michael Hotchkin.
What diseases does Clene aim to treat?
Clene focuses on neurodegenerative diseases like ALS, multiple sclerosis, and Parkinson’s disease.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLNN Insider Trading Activity
$CLNN insiders have traded $CLNN stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CLNN stock by insiders over the last 6 months:
- RESONANCE LLC GENERAL has made 0 purchases and 2 sales selling 4,001 shares for an estimated $20,585.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLNN Hedge Fund Activity
We have seen 19 institutional investors add shares of $CLNN stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SCOGGIN MANAGEMENT LP added 107,250 shares (+75.1%) to their portfolio in Q3 2025, for an estimated $646,181
- RENAISSANCE TECHNOLOGIES LLC added 30,440 shares (+inf%) to their portfolio in Q3 2025, for an estimated $183,401
- MARSHALL WACE, LLP added 22,709 shares (+inf%) to their portfolio in Q3 2025, for an estimated $136,821
- ENSIGN PEAK ADVISORS, INC added 14,880 shares (+inf%) to their portfolio in Q3 2025, for an estimated $89,652
- VANGUARD GROUP INC added 12,622 shares (+6.7%) to their portfolio in Q3 2025, for an estimated $76,047
- JANE STREET GROUP, LLC removed 12,095 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $72,872
- GEODE CAPITAL MANAGEMENT, LLC added 7,661 shares (+11.2%) to their portfolio in Q3 2025, for an estimated $46,157
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CLNN Analyst Ratings
Wall Street analysts have issued reports on $CLNN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 11/17/2025
- Benchmark issued a "Buy" rating on 09/10/2025
To track analyst ratings and price targets for $CLNN, check out Quiver Quantitative's $CLNN forecast page.
$CLNN Price Targets
Multiple analysts have issued price targets for $CLNN recently. We have seen 3 analysts offer price targets for $CLNN in the last 6 months, with a median target of $31.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $23.0 on 11/17/2025
- Bruce D. Jackson from Benchmark set a target price of $31.0 on 09/10/2025
- Sumant Kulkarni from Canaccord Genuity set a target price of $48.0 on 08/18/2025
Full Release
SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8 program in ALS, and to host an investor call and webcast at 8:30 am ET on Wednesday, December 3, 2025. The webcast is accessible via the link below or the Investors section of the Company’s website located here .
Webcast Information:
Title:
CNM-Au8 ALS Program Update
Presenters:
Rob Etherington, CEO and President, Dr. Ben Greenberg, Head of Medical, Michael Hotchkin, Chief Development Officer and a KOL
Date:
December 3, 2025
Start Time:
8:30 a.m. ET
Webcast link:
https://viavid.webcasts.com/starthere.jsp?ei=1744985&tp_key=9fb9583d33
Dial number:
1-877-407-0779 (US) or 1-201-389-0914 (international), Conference ID#13757380
The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8
®
is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8
®
is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on
X
(formerly
Twitter
) and
LinkedIn
.
About CNM-Au8
®
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8
®
is a federally registered trademark of Clene Nanomedicine, Inc.
Investor Contact
Kevin Gardner
LifeSci Advisors
[email protected]
617-283-2856
